Approximately 30% of the global population is affected by metabolic-associated fatty liver disease (MASLD), a condition that previously lacked targeted treatments. In a groundbreaking discovery, researchers have identified a genetic factor that exacerbates the disease, and remarkably, the FDA-approved drug that most effectively targets this factor is vitamin B3.
A collaborative research team led by Professor Jang Hyun Choi from the Department of Life Sciences at UNIST, in partnership with…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply